SREBF2 and Zika virus infectious disease: Pharmacologic or genetic inhibition of SREBP2 decreased ZIKV infection of moDCs by limiting cellular cholesterol content, which is likely to suppress ZIKV infection at the replication, assembly, and/or budding stages.